Sunday, November 15, 2026
Your Health 247
Advertisement
  • Home
  • Health
  • Fitness
  • Diseases
  • Nutrition
  • Weight Loss
  • Meditation
  • Wellbeing Tips
  • Suppliments
  • Yoga
No Result
View All Result
  • Home
  • Health
  • Fitness
  • Diseases
  • Nutrition
  • Weight Loss
  • Meditation
  • Wellbeing Tips
  • Suppliments
  • Yoga
No Result
View All Result
Your Health 247
No Result
View All Result
Home Health

FDA rejects ivonescimab, lung cancer treatment from Summit Therapeutics

Your Health 247 by Your Health 247
November 15, 2026
in Health
0 0
0
FDA rejects ivonescimab, lung cancer treatment from Summit Therapeutics
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter


Adam Feuerstein is a senior author and biotech columnist, reporting on the crossroads of drug improvement, enterprise, Wall Avenue, and biotechnology. He’s additionally a co-host of the weekly biotech podcast The Readout Loud and creator of the e-newsletter Adam’s Biotech Scorecard. You may attain Adam on Sign at stataf.54.

The Meals and Drug Administration rejected a therapy for a sort of lung most cancers developed by the U.S.-based biotech Summit Therapeutics and the Chinese language drugmaker Akeso, Summit mentioned on Sunday. 

In a letter despatched to the businesses, FDA regulators mentioned the drug, referred to as ivonescimab, couldn’t be accepted as a result of it didn’t assist sufferers reside longer. Whereas the drug was discovered to sluggish lung most cancers worsening in sufferers, the absence of a survival profit “doesn’t assist the optimistic benefit-risk profile in assist of approval,” FDA reviewers concluded. 

STAT Plus: Summit reveals blended outcomes from key research of lung most cancers drug

The FDA’s rejection of ivonescimab is a regulatory setback for Summit, which oversees improvement of the drug outdoors of China, though one which was not completely unexpected. 

STAT+ Unique Story

Have already got an account? Log in

STAT+

STAT+

This text is unique to STAT+ subscribers

Unlock this text — plus day by day protection and evaluation of the biotech sector — by subscribing to STAT+.

Have already got an account? Log in

Particular person plans

Group plans

View All Plans

To learn the remainder of this story subscribe to STAT+.

Subscribe



Source link

Tags: cancerFDAIvonescimablungrejectsSummitTherapeuticstreatment
Previous Post

‘You unpack once’: despite reports of ‘poop cruises’ and murder, cruise ships are more popular than ever | Cruises

Facebook Twitter Instagram Youtube RSS
Your Health 247

Discover the latest in health and fitness with Your Health 247. Get expert advice, workout routines, healthy recipes, and mental wellness tips to lead a healthier, happier life. Stay informed and empowered with us!

CATEGORIES

  • Diseases
  • Fitness
  • Health
  • Meditation
  • Nutrition
  • Suppliments
  • Weight Loss
  • Wellbeing Tips
  • Yoga
No Result
View All Result

SITEMAP

  • About Us
  • Advertise with Us
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Health
  • Fitness
  • Diseases
  • Nutrition
  • Weight Loss
  • Meditation
  • Wellbeing Tips
  • Suppliments
  • Yoga

Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In